Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SAI Life Sciences Ltd. ( (IN:SAILIFE) ) has shared an update.
Sai Life Sciences reported a strong set of unaudited results for the third quarter and nine months ended December 2025, with revenue from operations rising 27% year-on-year in Q3FY26 to ₹556 crore and 43% for the nine-month period to ₹1,590 crore. Profitability improved sharply, as EBITDA grew 54% in the quarter and 79% over nine months, while net profit nearly tripled for the nine months to ₹245 crore, lifting PAT margins to 15%. The performance was driven by robust growth across both CRO and CDMO services and underpinned by strategic initiatives including AI-driven retrosynthetic analysis and macrocyclic peptide design, centralization of photochemistry and electrochemistry capabilities, and expanded flow chemistry and high-throughput experimentation. The company has deployed ₹405 crore of its planned ₹700 crore FY26 capex, successfully cleared eight customer audits with no critical observations, and published its sixth sustainability report, signalling ongoing investment in capacity, quality, digitalisation and ESG, which collectively strengthen its competitive position in the global CRDMO market.
More about SAI Life Sciences Ltd.
Sai Life Sciences Limited is one of India’s fastest-growing Contract Research, Development and Manufacturing Organizations (CRDMO), providing CRO and CDMO services to pharmaceutical and biotech clients. Listed on both BSE and NSE, the Hyderabad-headquartered company focuses on discovery, development and manufacturing solutions, supported by investments in advanced technologies, automation and sustainability initiatives.
Average Trading Volume: 15,972
Technical Sentiment Signal: Buy
Current Market Cap: 170.9B INR
See more insights into SAILIFE stock on TipRanks’ Stock Analysis page.